v2.4.0.6

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Pharmaceutical products revenue		$ 27,219
Services revenue	10,653,015	3,689,310
Pharmaceutical products cost of revenue		24,797
Services cost of revenue	1,636,392	475,023
Business and sales related tax cost of revenue	583,046	220,490
Total Costs of Revenue	2,219,438	720,310
GROSS PROFIT	8,433,577	2,996,219
General and administrative expenses	353,931	142,551
Loss on inventory impairment		288,295
OPERATING INCOME	8,079,646	2,565,373
OTHER INCOME	20,611	1,610
INCOME BEFORE INCOME TAX	8,100,257	2,566,983
INCOME TAX	1,946,705	700,995
NET INCOME	6,153,552	1,865,988
LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS	303,952	93,688
NET INCOME ATTRIBUTABLE TO THE COMPANY	5,849,600	1,772,300
Foreign currency translation gain, net of tax	89,047	97,582
COMPREHENSIVE INCOME	5,938,647	1,869,882
LESS: OTHER COMPREHENSIVE INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS	5,857	3,767
COMPREHENSIVE INCOME ATTRIBUTABLE TO THE COMPANY	$ 5,932,790	$ 1,866,115
Basic and diluted earnings per common share	$ 0.15	$ 0.05
Weighted average number of shares outstanding	40,665,063	40,665,063

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

JINZANGHUANG TIBET PHARMACEUTICALS, INC. 10-K